Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
Recruiting · NCT04100174 · Interventional (participants receive a specific treatment) · Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
View the official record on ClinicalTrials.gov →Interventions studied
focal brachytherapy boost to SBRT
What this trial is about
To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL
Who can take part
Age range
No age limits stated
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
- ECOG 0-1
- Charlson Comorbidity Index ≤ 4
- Imaging visible disease encompassing \< 50% of the prostate gland and consistent with biopsy findings.
- Exclusion - none
Where it is running
2 locations listed.
- Centre Hospitalier de l'Université de Montréal - Montreal, Quebec, Canada
- CHUQ - Québec, Quebec, Canada